top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

Publications

  1. Bárez-López, S., Hartley, M.D., Grijota-Martínez, C., Scanlan, T.S. & Guadaño-Ferraz, A.  (2018).  Sobetirome and its amide prodrug Sob-AM2 exert thyromimetic actions in Mct8-deficient brain.  Thyroid 28, 1211-1220. View on PubMed.

  2. Aguayo-Mazzucato, C., Lee, Jr., T.B., Matzko, M., DiIenno, A., Rezanejad, H., Ramadoss, P., Scanlan, T., Zavacki, A.M., Larsen, P.R., Hollenberg, A., Colton, C., Sharma, A. & Bonner-Weir, S.  (2018).  T3 induces both markers of maturation and aging in pancreatic b-cells.  Diabetes 67, 1322-1331. View on PubMed.

  3. Devereaux, J., Ferrara, S.J. & Scanlan, T.S.  (2018).  Quantification of thyromimetic sobetirome concentration in biological tissue samples.  Thyroid Hormone Nuclear Receptor: Methods and Protocols, in: Methods Mol. Biol.  Eds, Plateroti, M. & Samarut, J., vol. 1801, ch. 16, pp 193-206. View on PubMed.

  4. Ferrara, S.J., Bourdette, D. & Scanlan, T.S.  (2018).  Hypothalamic-pituitary-thyroid axis perturbations in male mice by CNS-penetrating thyromimetics.  Endocrinology 159, 2733-2740. View on PubMed.

  5. Yu, G., Tzouvelekis, A., Wang, R., Herazo-Maya, J.D., Ibarra, G.H., Srivastava, A., Werneck de Castro, J.P., DeIuliis, G., Ahangari, F., Woolard, T., Aurelien, N., Arrojo e Drigo, R., Gan, Y., Graham, M., Liu, X., Homer, R.J., Scanlan, T.S., Mannam, P., Lee, P.J., Herzog, E.L., Bianco, A.C. & Kaminski, N.  (2018).  Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function.  Nature Med.  24, 39-49. View on PubMed.

  6. Meinig, J.M., Ferrara, S.J., Banerji, T., Banerji, T., Sanford-Crane, H.S., Bourdette, D. & Scanlan, T.S.  (2017).  Targeting fatty-acid amide hydrolase with prodrugs for CNS-selective therapy.  ACS Chem. Neurosci.  8, 2468-2476. View on PubMed.

  7. Ma, H., Yang, F., Butler, M.R., Belcher, J., Redmond, T.M., Placzek, A.T., Scanlan, T.S. & Ding, X.-Q.  (2017).  Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.  FASEB J.  31, 3425-3438. View on PubMed.

  8. Hartley, M.D., Kirkemo, L.L., Banerji, T. & Scanlan, T.S.  (2017).  A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy.  Endocrinology 158, 1328-1338. View on PubMed.

  9. Fernando, R., Placzek, E., Reese, E.A., Placzek, A.T., Schwartz, S., Trierweiler, A., Niziol, L.M., Raychaudhuri, N., Atkins, S., Scanlan, T.S. & Smith, T.J. (2017).  Elevated serum tetrac in Graves disease: potential pathogenic role in thyroid-associated ophthalmopathy.  J. Clin. Endocrinol. Metab.  102, 776-785. View on PubMed.

  10. Ferrara, S.J., Meinig, J.M., Placzek, A.T., Banerji, T., McTigue, P., Hartley, M.D., Sanford-Crane, H.S., Banerji, T., Bourdette, D. & Scanlan, T.S.  (2017).  Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration.  Bioorganic Med. Chem.  25, 2743-2753. View on PubMed.

  11. Bronchain, O.J., Chesneau, A., Monsoro-Burq, A.-H., Jolivet, P., Paillard, E., Scanlan, T.S., Demeneix, B.A., Sachs, L.M. & Pollet, N.  (2017).  Implication of thyroid hormone signaling in neural crest cells migration: evidence from thyroid hormone receptor beta knockdown and NH3 antagonist studies. Mol. Cell. Endocrinol.  439, 233-246. View on PubMed.

  12. Devereaux, J., Ferrara, S.J., Banerji, T., Placzek, A.T., Scanlan, T.S.  (2016).  Increasing thyromimetic potency through halogen substitution. ChemMedChem. 11, 2459-2465. View on PubMed.

  13. Placzek, A.T., Ferrara, S.J., Hartley, M.D., Sanford-Crane, H.S., Meinig, J.M. & Scanlan, T.S.  (2016).  Sobetirome prodrug esters with enhanced blood-brain barrier permeability. Bioorganic Med. Chem.  24, 5842-5854. View on PubMed.

  14. Placzek, A.T. & Scanlan, T.S.  (2015).  New synthetic routes to thyroid hormone analogs: d6-sobetirome, 3H-sobetirome, and the antagonist NH-3.  Tetrahedron 71, 5946-5951. View on PubMed.

  15. Guo, C., Chen, X., Song, H., Maynard, M.A., Zhou, Y., Lobanov, A.V., Gladyshev, V.N., Ganis, J.J., Wiley, D., Jugo, R.H., Lee, N.Y., Castroneves, L.A., Zon, L.I., Scanlan, T.S., Feldman, H.A. & Huang, S.A.  (2014).  Intrinsic expression of a multiexon type 3 deiodinase gene controls zebrafish embryo size.  Endocrinology 155, 4069-4080. View on PubMed.

  16. Gonçalves, L.M., Moreira, M.M., Azevedo, C.F., Valente, I.M., Sousa, J.C., Scanlan, T.S., Compton, R.G. & Rodrigues, J.A.  (2014).  Proof of concept of the electrochemical sensing of 3-iodothyronamine (T1AM) and thyronamine (T0AM).  ChemElectroChem 1, 1623-1626. View on PubMed.

  17. Haviland, J.A., Reiland, H., Butz, D.E., Tonelli, M., Porter, W.P., Zucchi, R., Scanlan, T.S., Chiellini, G. & Assadi-Porter, F.M.  (2013).  NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T1AM treatment.  Obesity 21, 2538-2544. View on PubMed.

  18. James, T.D., Moffett, S.X., Scanlan, T.S. & Martin, J.V.  (2013).  Effects of acute microinjections of the thyroid hormone derivative 3-iodothyronamine to the preoptic region of adult male rats on sleep, thermoregulation and motor activity.  Horm. Behav. 64, 81-88. View on PubMed.

  19. Hackenmueller, S.A. & Scanlan, T.S.  (2013).  Synthesis of 13C9-15N-labeled 3,5-diiodothyronine and thyroxine.  Synth. Commun.  43, 1439-1446. View on PubMed.

  20. Goldberg, I.J., Huang, L.-S., Huggins, L.A., Yu, S., Nagareddy, P., Scanlan, T.S. & Ehrenkrantz, J.  (2012).  Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.  Endocrinology 153, 5143-5149. View on PubMed.

  21. Hackenmueller, S.A. & Scanlan, T.S.  (2012).  Identification and quantification of 3-iodothyronamine metabolites in mouse serum using liquid chromatography-tandem mass spectrometry.  J. Chromatog. A. 1256, 89-97. View on PubMed.

  22. Hackenmueller, S.A., Marchini, M., Saba, A., Zucchi, R. & Scanlan, T.S.  (2012). Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T­4.  Endocrinology 153, 5659-5667. View on PubMed.

  23. Scanlan, T.S. & Fletterick, R.J.  (2012).  In Memoriam: John D. Baxter, M.D., 1940-2011.  Thyroid 22, 228-230. View on PubMed.

  24. Roy, G., Placzek, E. & Scanlan, T.S.  (2012).  ApoB-100 containing lipoproteins are major carriers of 3-iodothyronamine in circulation.  J. Biol. Chem. 287, 1790-1800. View on PubMed.

  25. Hoefig, C.S., Piehl, S., Scanlan, T.S., Bertoldi, M., Opladen, T., Hoffmann, G.F., Klein, J., Blankenstein, O., Schweizer, U. & Köhrle, J.  (2012).  Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis?  Mol. Cell. Endocrinol.  349, 195-201. View on PubMed.

  26. Wasik, A.M., Millan, M.J., Scanlan, T.S., Barnes, N.M. & Gordon, J.  (2012).  Evidence for functional trace amine associated receptor-1 in normal and malignant B cells.  Leukemia Res. 36, 245-249. View on PubMed.

  27. Galli, E., Marchini, M., Saba, A., Berti, S., Tonacchera, M., Vitti, P., Scanlan, T.S., Iervasi, G. & Zucchi, R.  (2012).  Detection of 3-iodothyronamine in human patients: a preliminary study.  J. Clin. Endocrinol. Metab.  97, E69-E74. View on PubMed.

  28. Agretti, P., De Marco, G., Russo, L., Saba, A., Raffaelli, A., Marchini, M., Chiellini, G., Grasso, L., Pinchera, A., Vitti, P., Scanlan, T.S., Zucchi, R. & Tonacchera, M.  (2011).  3-Iodothyronamine metabolism and functional effects in FRTL5 thyroid cells.  J. Mol. Endocrinol. 47, 23-32. View on PubMed.

  29. Scanlan, T.S.  (2011). Endogenous 3-iodothyronamine (T1AM): more than we bargained for.  J. Clin. Endocrinol. Metab.  96, 1674-1676. View on PubMed.

  30. Venditti, P., Napolitano, G., Di Stefano, L., Chiellini, G., Zucchi, R., Scanlan, T.S. & Di Meo, S.  (2011).  Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity.  Mol. Cell. Endocrinol. 341, 55-62. View on PubMed.

  31. Grijota-Martínez, C., Samarut, E., Scanlan, T.S., Morte, B. & Bernal, J.  (2011).  In vivo activity of the thyroid hormone receptor b-and a-selective agonists GC-24 and CO23 on rat liver, heart, and brain.  Endocrinology 152, 1136-1142. View on PubMed.

  32. Figueira, A.C.M., Saidenberg, D.M., Souza, P.C.T., Martínez, L., Scanlan, T.S., Baxter, J.D., Skaf, M.S., Palma, M. S., Webb, P.  & Polikarpov, I. (2011).  Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange.  Mol. Endocrinol. 25, 15-31. View on PubMed.

  33. Piehl, S., Hoefig, C.S., Scanlan, T.S. & Köhrle, J.  (2011).  Thyronamines-past, present, and future.  Endocrine Rev. 32, 64-80. View on PubMed.

  34. Roepke, T.A., Bosch, M.A., Rick, E.A., Lee, B., Wagner, E.J., Seidlova-Wuttke, D., Wuttke, W., Scanlan, T.S., Rønnekleiv, O.K. & Kelly, M.J.  (2010).  17b-Estradiol and the membrane ER ligand STX regulate body temperature and energy homeostasis in ovariectomized females.  Endocrinology 151, 4926-4937. View on PubMed.

  35. Saba, S., Chiellini, G., Frascarelli, S., Marchini, M., Ghelardoni, S., Rafaelli, A., Tonacchera, M., Vitti, P., Scanlan, T.S. & Zucchi, R.  (2010).  Tissue distribution and cardiac metabolism of 3-iodothyronamine.  Endocrinology 151, 5063-5073. View on PubMed.

  36. Martinez de Mena, R., Scanlan, T.S. & Obregon, M.-J.  (2010).  The T3 receptor b1 isoform regulates UCP1 and D2 deiodinase in rat.  Endocrinology 151, 5074-5083. View on PubMed.

  37. Lanculescu, A.G. & Scanlan, T.S.  (2010).  3-Iodothyronamine (T1AM): a new chapter in thyroid hormone endocrinology?  Mol. Biosyst. 12, 1338-1344. View on PubMed.

  38. Gompf, H.S., Greenberg, J.H., Aston-Jones, G., Ianculescu, A., Scanlan, T.S. & Dratman, M.B.  (2010).  3-Monoiodothyronamine: the rationale for its action as an endogenous adrenergic-blocking neuromodulator. Brain Res. 1351, 130-140. View on PubMed.

  39. Venditti, P., Chiellini, G., Di Stefano, L., Napolitano, G., Zucchi, R., Columbano, A., Scanlan, T.S. & Di Meo, S.  (2010). The TRb-selective agonist GC-1 stimulates mitochondrial oxidative processes to a lesser extent then T3.  J. Endocrinol. 205, 279-289. View on PubMed.

  40. Hettinger, B.A., Schuff, K.G. & Scanlan, T.S.  (2010).  3-Iodothyronamine (T1AM): a new thyroid hormone?  Thyroid International 2, 1-12. View on PubMed.

  41. Lanculescu, A.G., Friesema, E.C.H., Visser, T.J., Giacomini, K.M. & Scanlan, T.S.  (2010).  Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine.  Mol. Biosyst. 12, 1403-1410. View on PubMed.

  42. Roohk, D.J., Cuzzocrea, S., Varady, K.A., Turner, S.M., Emson, C.E., Gelling, R.W., Shankaran, M., Lindwall, G., Shipp, L.E., Scanlan, T.S., Wang, J.-C. & Hellerstein, M.K.  (2010).  Differential in vivo effects on target pathways of a novel arylpyrazole glucocorticoid receptor modulator compared with prednisolone.  J. Pharm. Exp. Therap.  333, 281-289. View on PubMed.

  43. Schreiber, T., Gassmann, K., Götz, C., Hübenthall, U., Moors, M., Krause, G., Merk, H.F., Croften, K.M., Nguyen, N.-H., Scanlan, T.S., Abel, J., Rose, C., Fritsche, E.  (2010). Polybrominated diphenyl ethers induce developmental neurotoxicity in a human in vitro model: evidence for endocrine disruption.  Environ. Health Perspect. 118, 572-578. View on PubMed.

  44. Panas, H.N., Lynch, L., Vallender, E.J., Xie, Z., Chen, G., Lynn, S.K., Scanlan, T.S. & Miller, G.M.  (2010).  Normal thermoregulatory responses of 3-iodothyronamine, trace amines or amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice.  J. Neurosci. Res. 88, 1962-1969. View on PubMed.

  45. Scanlan, T.S.  (2010). Sobetirome:  a case history of bench-to-clinic drug discovery & development.  Heart Fail. Rev. 15, 177-182. View on PubMed.

  46. Cunha Lima, S.T., Nguyen, N.-H., Togashi, M., Apriletti, J.W., Nguyen, P., Polikarpov, I., Scanlan, T.S., Baxter, J.D. & Webb, P.  (2009).  Differential effects of TR ligands on hormone dissociation rates: evidence for multiple ligand entry/exit pathways.  J. Steroid Biochem. Mol. Biol.  117, 125-131. View on PubMed.

  47. Lin, B.C ., Suzawa, M., Blind, R.D.,Tobias, S.C., Bulun, S.E., Scanlan, T.S. & Ingraham, H.A.  (2009). Estrogen ligand stimulation of the GPR30 transmembrane receptor activates SF-1/LRH-1 nuclear receptors and increases proliferation in endometrial cells.  Cancer Res.  69, 5415-5423. View on PubMed.

  48. Klieverik, L.P., Foppen, E., Ackermans, M.T., Serlie, M.J., Sauerwein, H.P., Scanlan, T.S., Grandy, D.K., Fliers, E. & Kalsbeek, A.  (2009).  Central effects of thyronamines on glucose metabolism in rats.  J. Endocrinol.  201, 377-386. View on PubMed.

  49. Ghelardoni, S., Suffredini, S., Frascarelli, S., Brogioni, S., Chiellini, G., Ronca-Testoni, S., Grandy, D.K., Scanlan, T.S. & Cerbai, E. & Zucchi, R.  (2009).  Modulation of cardiac ionic homeostasis by 3-iodothyronamine.  J. Cell. Mol. Med.  13, 3082-3090. View on PubMed.

  50. Venditti, P., Chiellini, G., Bari, A., Di Stefano, L., Zucchi, R, Columbano, A., Scanlan, T.S. & Di Meo, S.  (2009).  T3 and the thyroid hormone b-receptor agonist GC-1 differentially affect metabolic capacity and oxidative damage in rat tissues.  J. Exp. Biol.  212, 986-993. View on PubMed.

  51. Tan, E.S., Naylor, J.C., Groban, E.S., Bunzow, J.R., Jacobson, M.P., Grandy, D.K. & Scanlan, T.S.  (2009).  The molecular basis of species-specific ligand activation of trace amine-associated receptor 1 (TAAR1).  ACS Chem. Biol.  4, 209-220. View on PubMed.

  52. Scanlan, T.S.  (2009).  3-Iodothyronamine (T1AM):  a new player on the thyroid endocrine team?  Endocrinology 150, 1108-1111. View on PubMed.

  53. Lanculescu, A.G., Giacomini, K.M. & Scanlan, T.S.  (2009). Identification and characterization of 3-iodothyronamine (T1AM) intracellular transport.  Endocrinology 150, 1991-1999. View on PubMed.

  54. Beber, E.H., Capelo, L.P., Fonseca, T.L., Costa, C.C., Lotfi, C.F., Scanlan, T.S. & Gouveia, C.H.A.  (2009).  The thyroid hormone receptor (TR) b-selective agonist GC-1 inhibits proliferation but induces differentiation and TRb mRNA expression in mouse and rat osteoblast-like cells.  Calcif. Tissue Int. 84, 324-333. View on PubMed.

  55. Denver, R.J., Hu, F., Scanlan, T.S. & Furlow, J.D.  (2009).  Thyroid hormone receptor subtype specificity for hormone-dependent neurogenesis in Xenopus laevis.  Dev. Biol. 326, 155-168. View on PubMed.

  56. Wood, W.J.L., Geraci, T., Nilsen, A., DeBarber, A.E. & Scanlan, T.S.  (2009).  Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo.  ChemBioChem. 10, 361-365. View on PubMed.

  57. Shah, V., Nguyen, P., Nguyen, N.-H., Togashi, M., Scanlan, T.S., Baxter, J.D. & Webb, P.  (2008).  Complex actions of the thyroid hormone receptor antagonist (NH-3) on gene promoters in different cell lines.  Mol. Cell. Endocrinol. 296, 69-77. View on PubMed.

  58. DeBarber, A.E., Geraci, T., Colasurdo, V.P., Hackenmueller, S.A. & Scanlan, T.S.  (2008).  Validation of a liquid chromatography-tandem mass spectrometry method to enable quantification of 3-iodothyronamine from serum.  J. Chromatog. A 1210, 55-59. View on PubMed.

  59. Piehl, S., Heberer, T., Balizs, G., Scanlan, T.S. & Köhrle, J.  (2008).  Development of a validated liquid chromatography/tandem mass spectrometry method for the distinction of thyronine and thyronamine constitutional isomers and for the identification of new deiodinase substrates.  Rapid Commun. Mass Spectrom. 22, 3286-3296.

  60. Roepke, T.A., Xue, C., Bosch, M.A., Scanlan, T. S., Kelly, M.J. and Rønnekleiv, O.K.  (2008). Genes associated with membrane-initiated signaling of estrogen and energy homeostasis. Endocrinology 149, 6113-6124.

  61. Snead, A.N., Miyakawa, M., Tan, E.S. & Scanlan, T.S.  (2008).  Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites.  Bioorganic Med. Chem. Lett. 18, 5920-5922.

  62. Jeyakumar, M., Webb, P., Baxter, J.D., Scanlan, T.S. & Katzenellenbogen, J.A.  (2008).  Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. Biochemistry 47, 7465-7476.

  63. Paris, M., Escriva, H., Schubert, M., Brunet, F., Brtko, J., Ciesielski, F., Roecklin, D., Vivat-Hannah, V., Jamin, E.L., Cravedi, J.-P., Scanlan, T.S., Renaud, J.-P., Holland, N.D. & Laudet, V.  (2008). Amphioxus postembryonic development reveals the homology of chordate metamorphosis.  Curr. Biol. 18, 825-830.

  64. Frascarelli, S., Ghelardoni, S., Chiellini, G., Vargiu, R., Ronca-Testoni, S., Scanlan, T.S., Grandy, D.K. & Zucchi, R.  (2008).  Cardiac effects of trace amines: pharmacological characterization of trace amine-associated receptors.  Eur. J. Pharmacol.  587, 231-236.

  65. Scanlan, T.S.  (2008).  Thyroid hormone analogues: useful biological probes and potential therapeutic agents.  Ann. Endocinol.  69, 157-159.

  66. Tan, E.S., Groban, E.S.; Jacobson, M.P. & Scanlan, T.S.  (2008).  Deciphering the code to aminergic G protein-coupled receptor drug design.  Chem. Biol. 15, 343-353.

  67. Piehl, S., Heberer, T., Balizs, G., Scanlan, T.S., Smits, R. & Köhrle, J.  (2008).  Identification of thyronamines as isozyme specific deiodinase substrates.  Endocrinology 149, 3037-3045.

  68. Ocasio, C.A. & Scanlan, T.S.  (2008).  Characterization of thyroid hormone receptor a (TRa)-specific analogs with varying inner- and outer-ring substituents.  Bioorganic Med. Chem.  16, 762-770.  

  69. Braulke, L.J., Klingenspor, M., DeBarber, A., Tobias, S.C., Grandy, D.K., Scanlan, T.S. & Heldmaier, G.  (2008).  3-Iodothyronamine:  a novel hormone controlling the balance between glucose and lipid utilisation.  J. Comp. Physiol. B  178, 167-177.

  70. Regard, J.B., Kataoka, H., Cano, D.A., Camerer, E., Yin, L., Zheng, Y.-W., Scanlan, T.S., Hebrok, M. & Coughlin, S.R.  (2007).  Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion.  J. Clin. Invest. 12, 4034-4043.

  71. Doyle, K.P., Suchland, K.L., Ciesielski, T.M.P., Lessov, N.S., Grandy, D.K., Scanlan, T.S. & Stenzel-Poore, M.P.  (2007).  Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked neuroprotection against stroke injury.  Stroke 38, 2569-2576.

  72. Snead, A.N., Santos, M.S., Seal, R.P., Miyakawa, M., Edwards, R.H. & Scanlan, T.S.  (2007).  Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem. Biol. 2, 390-398.

  73. Grover, G.J., Dunn, C., Nguyen, N.-H., Boulet, J., Dong, G., Domogaver, J., Barbounis, P. & Scanlan, T.S.  (2007).  Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats.  J. Pharmacol. Exp. Ther. 322, 385-390.

  74. Tan, E.S., Miyakawa, M., Bunzow, J.R., Grandy, D.K. & Scanlan, T.S.  (2007).  Exploring the structure-activity relationship of the ethylamine portion of 3-iodothyronamine for the rat and mouse trace amine-associated receptor 1.  (2007).  J. Med. Chem.  50, 2787-2798.

  75. Chiellini, G., Frascarelli, S. Ghelardoni, S., Carnicelli, V., Tobias, S.C., DeBarber, A., Brogioni, S., Ronca-Testoni, S., Cerbai, E., Grandy, D.K., Scanlan, T.S. & Zucchi, R.  (2007).  Cardiac effects of 3-iodothyronamine:  a new aminergic system modulating cardiac function.  FASEB J. 21, 1597-1608.

  76. Pietsch, C.A., Scanlan, T.S. & Anderson, R.J.  (2007). Thyronamines are substrates for human liver sulfotransferases (SULTs).  Endocrinology 148, 1921-1927.

  77. Villicev, C.M., Freitas, F.R.S., Aoki, M.S., Taffarel, C., Scanlan, T.S., Moriscot, A.S., Ribeiro, M.O., Bianco, A.C. & Gouveia, C.H.A.  (2007).  Thyroid hormone receptor b-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats.  J. Endocrinol. 193, 21-29.

  78. Cvoro, A., Paruthiyil, S., Jones, J., Tzagarakis-Foster, C., Clegg, N.J., Tatomer, D., Medina, R.T., Tagliaferri, M., Schaufele, F., Scanlan, T.S., Diamond, M.I. & Leitman, D.C.  (2006).  Selective activation of estrogen receptor-b transcriptional pathways by an herbal extract.  Endocrinology 148, 538-547.

  79. Havis, E., Le Mevel, S., Morvan DuBois, G., Shi, D.-L., Scanlan, T.S., Demeneix, B.A. & Sachs, L.M.  (2006).  Unliganded thyroid hormone receptor is essential for Xenopus laevis eye development.  EMBO J.  25, 4943-4951.

  80. Zucchi, R., Chiellini, G., Scanlan, T.S. & Grandy, D.K.  (2006).  Trace amine-associated receptors and their ligands.  Br. J. Pharmcol.  149, 967-978.

  81. Flamant, F., Baxter, J.D., Forrest, D., Refetoff, S., Samuels, H., Scanlan, T.S., Vennstrom, B. & Samarut, J.  (2006). International Union of Pharmacology.  LIX.  The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors.  Pharmacol. Rev. 58, 705-711.

  82. Ocasio, C.A. & Scanlan, T.S.  (2006).  Design and characterization of a thyroid hormone receptor a (TRa)-specific agonist.  ACS Chem. Biol. 1, 585-593.

  83. Hiroi, Y., Kim, H.-H., Ying, H., Furaya, F., Huang, Z., Simoncini, T., Noma, K., Ueki, K., Nguyen, N.-H., Scanlan, T.S., Moskowitz, M.A., Cheng, S.-Y. & Liao, J.K.  (2006).  Rapid nongenomic actions of thyroid hormone.  Proc. Natl. Acad. Sci. 103, 14104-14109.

  84. Qiu, J., Bosch, M.A., Tobias, S.C., Krust, A., Graham, S.M., Murphy, S.J., Korach, K.S., Chambon, P., Scanlan, T.S., Rønnekleiv, O.K. & Kelly, M.J.  (2006).  Estrogen controls energy homeostasis via a G protein-coupled signaling pathway in hypothalamic neurons.  J. Neurosci. 26, 5649-5655.

  85. Columbano, A., Pibiri, M., Deidda, M., Cossu, C., Scanlan, T.S., Chiellini, G., Muntoni, S. & Ledda-Columbano, G.M.  (2006).  The thyroid hormone receptor-b agonist GC-1 induces cell proliferation in rat liver and pancreas.  Endocrinology 147, 3211-3218.

  86. Wang, J.-C., Shah, N., Pantoja, C., Ho, J., Scanlan, T.S. & Yamamoto, K.R.  (2006).  Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity.  Genes Dev. 20, 689-699.

  87. Tobias, S.C., Qiu, J., Kelly, M.J. & Scanlan, T.S.  (2006).  Synthesis and biological evaluation of novel SERMs with potent non-genomic estrogenic activity that lack genomic activity.  ChemMedChem 1, 565-571.

  88. Hart, M.E., Suchland, K.L., Miyakawa, M., Bunzow, J.R., Grandy, D.K. & Scanlan, T.S.  (2006).  Trace amine receptor agonists: synthesis and evaluation of thyronamines and related analogues.  J. Med. Chem. 49, 1101-1112.  

  89. Miyakawa, M. & Scanlan, T.S.  (2006).  Synthesis of [125I]-, [2H]-, and [3H]-labeled 3-iodothyronamine (T1AM).  Synth. Commun. 36, 891-902.

  90. Optiz, R., Lutz, I., Nguyen, N.-H., Scanlan, T.S. & Kloas, W.  (2006).  Analysis of thyroid hormone receptor bA mRNA expression in Xenopus laevis tadpoles as a means to detect agonism and antagonism of thyroid hormone action.  Toxicol. Appl. Pharmacol. 212, 1-13.

  91. Lin, B.C. & Scanlan, T.S.  (2005).  Few things in life are free: cellular uptake of steroid hormones by an active transport mechanism.  Mol. Interventions 5, 338-340.

  92. Gloss, B., Giannocco, G., Swanson, E.A., Moriscot, A.S., Chiellini, G., Scanlan, T.S., Baxter, J.D. & Dillmann, W.H.  (2005).  Different configurations of specific thyroid hormone response elements mediate opposite effects of T3 and GC-1 on gene expression.  Endocrinology 146, 4926-4933.

  93. Clegg, N.J., Paruthiyil, S., Leitman, D.C. & Scanlan, T.S.  (2005).  Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.  J. Med. Chem. 48, 5989-6003.

  94. Ocasio, C.A. & Scanlan, T.S.  (2005).  Clinical prospects of new thyroid hormone analogs.  Curr. Opin. Endocrinol. Diabetes 12, 363-370.  

  95. Mousa, S.A., O’Connor, L., Davis, F.B., Scanlan, T.S. & Davis, P.J.  (2005).  The pro-angiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin.  J. Cardiovasc. Pharmacol. 46, 356-360.

  96. Johansson, L., Rudling, M., Scanlan, T.S., Lundasen, T., Webb, P., Baxter, J., Angelin, B. & Parini, P.  (2005).  Selective thyroid hormone modulation by GC-1 reduces serum lipid and stimulates steps of reverse cholesterol transport in euthyroid mice.  Proc. Natl. Acad. Sci. 102, 10297-10302.

  97. Miyabara, E.H., Aoki, M.S., Soares, A.G., Saltao, R.M., Vilicev, C.M., Passarelli, M., Scanlan, T.S., Gouveia, C.H. & Moriscot, A.S.  (2005).  Thyroid hormone receptor-b-selective agonist GC-24 spares skeletal muscle type I to II fiber shift.  Cell Tissue Res. 321, 233-241.

  98. Fritsche, E., Cline, J.E., Nguyen, N.-H., Scanlan, T.S. & Abel, J.  (2005).  Polychlorinated biphenyls disturb differentiation of normal human neural progenitor cells: clue for involvement of thyroid hormone receptors.  Environ. Health Perspect. 113, 871-876.

  99. Nguyen, N.-H., Apriletti, J.W., Baxter, J.D. & Scanlan, T.S.  (2005).  Hammett analysis of selective thyroid hormone receptor modulators reveals structure and electronic requirements for hormone antagonists.  J. Am. Chem. Soc. 127, 4599-4608.

  100. Freitas, F.R.S., Capelo, L.P., O’Shea, P.J., Jorgetti, V., Moriscot, A.S., Scanlan, T.S., Williams, G.R., Zorn, T.M.T. & Gouveia, C.H.A.  (2005).  The thyroid hormone receptor b-specific agonist GC-1 selectively affects the bone development of hypothyroid rats.  J. Bone Miner. Res. 20, 294-304.

  101. Shah, N. & Scanlan, T.S.  (2004).  Design and evaluation of novel non-steroidal dissociating glucocorticoid receptor ligands.  Bioorganic Med. Chem. Lett.  14, 5199-5203.

  102. Scanlan, T.S., Suchland, K.L., Hart, M.E., Chiellini, G., Huang, Y., Frascarelli, S., Kruzich, P.J., Crossley II, D.A., Bunzow, J.R., Ronca-Testoni, S., Lin, E.T., Hatton, D., Zucchi, R. & Grandy, D.K.  (2004).  3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone.  Nature Med. 10, 638-642.

  103. Baxter, J.D., Webb, P., Grover, G. & Scanlan, T.S.  (2004).  Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight.  Trends Endocrinol. Metab. 15, 154-157.

  104. Moore, J.M., Galicia, S.J., McReynolds, A.C., Nguyen, N.H., Scanlan, T.S. & Guy, R.K.  (2004).  Quantitative proteomics of the thyroid hormone receptor coregulator interactions.  J. Biol. Chem. 279, 27584-27590.

  105. Mishra, M.K., Wilson, F.E., Scanlan, T.S. & Chiellini, G.  (2004).  Thyroid hormone-dependent seasonality in American tree sparrows (Spizella arborea): effects of GC-1, a thyroid receptor b-selective agonist, and of iopanoic acid, a deiodinase inhibitor.  J. Comp. Physiol. B 174, 471-479.

  106. Furlow, J.D., Yang, H.Y., Hsu, M., Lim, W., Ermio, D.J., Chiellini, G. & Scanlan, T.S.  (2004). Induction of larval tissue resorption in Xenopus laevis tadpoles by the thyroid hormone receptor agonist GC-1.  J. Biol. Chem. 279, 26555-26562.

  107. Dupre, S.M., Guissouma, H., Flamant, F., Seugent, I., Scanlan, T.S., Baxter, J.D., Samarut, J., Becker, N. & Demeneix, B.A.  (2004).  Both thyroid hormone receptor (TR)b1 and TRb2 isoforms contribute to regulation of hypothalamic thyrotropin-releasing hormone.  Endocrinology 145, 2337-2345.

  108. Grover, G.J., Egan, D.M., Sleph, P.G., Beehler, B.C., Chiellini, G., Nguyen, N.-H., Baxter, J.D. & Scanlan, T.S.  (2004).  Effects of the thryoid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates:  selective actions relative to 3,5,3’-triiodo-L-thyronine. Endocrinology 145, 1656-1661.  

  109. Morte, B., Manzano, J., Scanlan, T.S., Vennstrom, B. & Bernal, J.  (2004).  Aberrant maturation of astrocytes in the thyroid hormone receptor a1 knock out mice reveals an interplay between thyroid hormone receptor isoforms.  Endocrinology 145, 1386-1391.

  110. Borngraeber, S., Budny, M.-J., Chiellini, G., Cunha-Lima, S.T., Togashi, M., Webb, P., Baxter, J.D., Scanlan, T.S. & Fletterick, R.J.  (2003).  Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor.  Proc. Natl. Acad. Sci. 100, 15358-15363.

  111. Manzano, J., Morte, B., Scanlan, T.S. & Bernal, J.  (2003).  Differential effects of triiodothyronine and the thyroid hormone receptor beta-specific agonist GC-1 on thyroid hormone target genes in the brain.  Endocrinology 144, 5480-5487.

  112. Qiu, J., Bosch, M.A., Tobias, S., Grandy, D.K., Scanlan, T.S., Rønnekleiv, O.K. & Kelly, M.J.  (2003).  Rapid signaling of estrogen in hypothalamic neurons involves a novel G protein-coupled estrogen receptor that activates protein kinase C.  J. Neurosci. 23, 9529-9540.

  113. Yoshihara, H.A.I., Apriletti, J.W., Baxter, J.D. & Scanlan, T.S.  (2003). Structural determinants of selective thyromimetics.  J. Med. Chem. 46, 3152-3161.

  114. Chong, L.T., Bandyopadhyay, P., Scanlan, T.S., Kuntz, I.D., Kollman, P.A.  (2003).  Direct hydroxide attack is a plausible mechanism for amidase antibody 43C9.  J. Comput. Chem. 24, 1371-1377.

  115. Wade, H. & Scanlan, T.S.  (2003).  A thermodynamic analysis of transition-state analog binding and transition-state stabilization for a catalytic antibody.  ChemBioChem 4, 537-540.  

  116. Freitas, F.R.S., Moriscot, A.S., Jorgetti, V., Soares, A.G., Passarelli, M., Scanlan, T.S., Brent, G.A., Bianco, A.C. & Gouveia, C.H.A.  (2003).  Spared bone mass in rats treated with thyroid hormone receptor TRb-selective compound GC-1.  Am. J. Physiol. Endocinol. Metab. 285, E1135-E1141.

  117. Yoshihara, H.A.I. & Scanlan, T.S.  (2003).  Selective thyroid hormone receptor modulators.  Curr. Top. Med. Chem. 3, 1601-1616.

  118. Yoshihara, H.A.I., Nguyen, N.-H. & Scanlan, T.S.  (2003).  Design and synthesis of receptor ligands.  Meth. Enzymol. 364, 71-91.

  119. Webb, P., Nguyen, N.-H., Chiellini, G., Yoshihara, H.A.I., Cunha Lima, S.T., Apriletti, J.W., Ribeiro, R.C.J., Marimutha, A., West, B.L., Goede, P., Mellstrom, K., Nilsson, S., Kushner, P.J., Fletterick, R.J., Scanlan, T.S. & Baxter, J.D.  (2003).  Design of thyroid hormone receptor antagonists from first principles.  J. Steroid Biochem. Mol. Biol. 83, 59-73.

  120. Lim, W., Nguyen, N.-H., Yang, H.Y., Scanlan, T.S. & Furlow, J.D.  (2002).  A thyroid hormone antagonist that inhibits thyroid hormone action in vivo.  J. Biol. Chem. 277, 35664-35670.

  121. Nguyen, N.-H., Apriletti, J.W., Cunha Lima, S.T., Webb, P., Baxter, J.D. & Scanlan, T.S.  (2002).  Rational design and synthesis of a novel thyroid hormone antagonist that blocks co-activator recruitment.  J. Med. Chem. 45, 3310-3320.

  122. Baxter, J.D., Goede, P., Apriletti, J.W., West, B., Feng, W., Mellstrom, K., Fletterick, R.J., Wagner, R.L., Kushner, P.J., Ribeiro, R.C.J., Webb, P., Scanlan, T.S., Nilsson, S.  (2002).  Structure-based design and synthesis of a thyroid hormone receptor antagonist. Endocrinology 143, 517-524.

  123. Weatherman, R.V., Chang, C.-Y., Clegg, N.C., Carroll, D.C., Day, R.N., Baxter, J.D., McDonnell, D.P., Scanlan, T.S. & Schaufele, F.  (2002).  Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.  Mol. Endocrinol. 16, 487-496.

  124. Morte, B., Manzano, J., Scanlan, T.S., Vennstrom, B. & Bernal, J.  (2002).  Deletion of the thyroid hormone receptor a1 prevents the structural alterations of the cerebellum induced by hypothyroidism.  Proc. Natl. Acad. Sci. 99, 3985-3989.

  125. Weatherman, R.V., Carroll, D.C. & Scanlan, T.S.  (2001).  Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site.  Bioorg. Med. Chem. Lett. 11, 3129-3131.

  126. Scanlan, T.S., Yoshihara, H.A.I., Nguyen, N.-H. & Chiellini, G.  (2001).  Selective thyromimetics:  tissue selective thyroid hormone analogs.  Curr. Opin. Drug Discov. Dev. 4, 614-622.

  127. Chiellini, G., Nguyen, N.-H., Apriletti, J.W., Baxter, J.D. & Scanlan, T.S.  (2001).  Synthesis and biological activity of novel thyroid hormone analogs:  5’-aryl substituted GC-1 derivatives.  Bioorg. Med. Chem. 10, 333-346.

  128. Yoshihara, H.A.I., Apriletti, J.W., Baxter, J.D. & Scanlan, T.S.  (2001).  A designed antagonist of the thyroid hormone receptor.  Bioorg. Med. Chem. Lett. 11, 2821-2825.

  129. Ribeiro, M.O., Carvalho, S.D., Schultz, J.J., Chiellini, G., Scanlan, T.S., Bianco, A.C., & Brent, G.A.  (2001).  Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific.  J. Clin. Invest. 108, 97-105.

  130. Baxter, J.D., Dillmann, W.H., West, B.L., Huber, R., Furlow, J.D., Fletterick, R.J., Webb, P., Apriletti, J.W., Scanlan, T.S.  (2001).  Selective modulation of thyroid hormone receptor action.  J. Steroid Biochem. Molec. Biol. 76, 31-42.

  131. Wagner, R.L., Shiau, A.K., Huber, B.R., Kelly, A., Cunha Lima, S.T., Scanlan, T.S., Apriletti, J.W., Baxter, J.D, West, B.L., & Fletterick, R.J.  (2001).  Hormone selectivity in thyroid hormone receptors.  Mol. Endocrinol. 15, 398-410.

  132. Weatherman, R.W., Clegg, N.J. & Scanlan, T.S.  (2001).  Differential SERM activation of estrogen receptors (ERa and ERb) at AP-1 sites.  Chem. Biol.  8, 427-436.

  133. Weatherman, R.C. & Scanlan, T.S. (2001).  Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ERa and ERb) at AP-1 sites.  J. Biol. Chem. 276, 3827-3832.

  134. Person, E.C., Waite, L.L., Taylor, R.N. & Scanlan, T.S.  (2001). Albumin regulates induction of peroxisome proliferator-activated receptor-g (PPARg) by 15-deoxy-D12,14-prostaglandin J2 in vitro and may be an important regulator of PPARg function in vivo.  Endocrinology 142, 551-556.  

  135. Webb, P., Nguyen, P., Valentine, C., Weatherman, R., Scanlan, T.S. & Kushner, P.J.  (2000).  An antiestrogen-responsive estrogen receptor-a mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen.  J. Biol. Chem. 275, 37552-37558.

  136. Bogan, A.A., Dallas-Yang, Q., Ruse, M.D., Maeda, Y., Jiang, G., Nepomuceno, L., Scanlan, T.S., Cohen, F.E. & Sladek, F.M.  (2000).  Analysis of protein dimerization and ligand binding of orphan receptor HNF4a.  J. Mol. Biol. 302, 831-851.

  137. Kushner, P.J., Agard, D.A., Greene, G.L., Scanlan, T.S., Shiau, A.K., Uht, R.M. & Webb, P.  (2000).  Estrogen receptor pathways to AP-1.  J. Steroid Biochem. Molec. Biol. 74, 311-317.

  138. Chiellini, G., Nguyen, N.-H., Yoshihara, H.A.I. & Scanlan, T.S.  (2000).  Improved synthesis of the iodine-free thyromimetic GC-1.  Bioorg. Med. Chem. Lett. 10, 2607-2611.

  139. Waite, L.L., Person, E.C., Zhou, Y., Lim, K.-H., Scanlan, T.S. & Taylor, R.N.  (2000).  Placental peroxisome proliferator-activated receptor-g is upregulated by pregnancy serum.  J. Clin. Endocrinol. Metab. 85, 3808-3814.

  140. Trost, S.U., Swanson, E., Gloss, B.,Wang-Iverson, D.B., Zhang, H., Volodarsky, T., Grover, G.J., Baxter, J.D., Chiellini, G., Scanlan, T.S. & Dillmann, W.H.  (2000).  The thyroid hormone receptor-b-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.  Endocrinology 141, 3057-3064.

  141. Wade, H. & Scanlan, T.S.  (1999).  Expression of binding energy on an antibody reaction coordinate.  J. Am. Chem. Soc 121, 11,935-11941.

  142. Weatherman, R.C., Fletterick, R.J. & Scanlan, T.S.  (1999).  Nuclear receptor ligands and ligand binding domains.  Annu. Rev. Biochem.  68, 559-581.

  143. Wade, H. & Scanlan, T.S.  (1999).  Remote binding energy in antibody catalysis:  studies of a catalytically unoptimized specificity pocket.  J. Am Chem. Soc.  121, 1434-1443.

  144. Apriletti, J.W., Ribeiro, R.C.J., Wagner, R.L., Feng, W., Webb, P., Kushner, P.J., West, B.L., Nilsson, S., Scanlan, T.S., Fletterick, R.J., & Baxter, J.D.  (1998).  Molecular and structural biology of thyroid hormone receptors.  Clin. Exper. Pharmacol. Physiol.  25, S2-S11.

  145. Webb, P., Keneally, M.-R., Shinsako, J., Uht, R., Anderson, C., Paech, K., Scanlan, T.S. & Kushner, P.J.  (1998).  The ER/AP-1 pathway:  a window on the cell-specific estrogen-like effects of antiestrogens.  In Molecular Basis of Sex Hormone Receptor Function.  (H. Gronemeyer, U. Fuhrmann, K. Parczyk, eds.), pp 121-140, Springer-Verlag, Berlin.

  146. Ribeiro, R.C.J., Apriletti, J.W., Wagner, R.L., Feng, W., Kushner, P.J., Nilsson, S., Scanlan, T.S., West, B.L., Fletterick, R.J., & Baxter, J.D. (1998).  X-ray crystallographic and functional studies of thyroid hormone receptor.  J. Steroid Biochem. Molec. Biol. 65, 133-141.

  147. Bogan, A.A., Cohen, F.E. & Scanlan, T.S. (1998).  Natural ligands of nuclear receptors have conserved volumes.  Nature Struct. Biol. 5, 679-681.

  148. Chiellini, G., Apriletti, J.W., Yoshihara, H.A.I., Baxter, J.D., Ribeiro, R.C.J. & Scanlan, T.S. (1998).  A high affinity subtype-selective agonist ligand for the thyroid hormone receptor.  Chem. Biol. 5, 299-306.

  149. Yoshihara, H.A.I, Chiellini, G., Mitchison, T.J. & Scanlan, T.S. (1998).  An efficient substitution reaction for the preparation of thyroid hormone analogues.  Bioorganic Med. Chem. 6, 1179-1183.

  150. Buchbinder, J.L., Stephenson, R.C., Scanlan, T.S., Fletterick, R.J. (1998).  A comparison of the crystallographic structures of two catalytic antibodies with esterase activity.  J. Mol. Biol. 282, 1033-1041.

  151. Ribeiro, R.C.J., Apriletti, J.W., Wagner, R.L., West, B.L., Feng, W., Huber, R., Kushner, P.J., Nilsson, S., Scanlan, T.S., Fletterick, R.J., Schaufele, F. & Baxter, J.D. (1998).  Mechanisms of thyroid hormone action:  insights from x-ray crystallographic and functional studies.  Rec. Prog. Hormone Res. 53, 351-394.

  152. Miller, S.C. & Scanlan, T.S. (1998).  oNBS-SPPS:  a new method for solid-phase peptide synthesis.  J. Am. Chem. Soc. 120, 2690-2691.

  153. Buchbinder, J.L., Stephenson, R.C., Dresser, M., Pitera, J., Scanlan, T.S. & Fletterick, R.J. (1998).  Biochemical characterization and crystallographic structure of an Escherichia coli protein from the phosphotriesterase gene family.  Biochemistry 37, 5096-5106.

  154. Bishop, A.C., Moore, D., Scanlan, T.S. & Shokat, K.M. (1997).  Screening a hydroxystilbene library for selective inhibition of the B cell antigen receptor kinase cascade.  Tetrahedron 53, 11995-12004.

  155. Fox, T., Scanlan, T.S. & Kollman, P.A. (1997).  Ligand-binding in the catalytic antibody 17E8:  a free energy perturbation calculation study.  J. Am. Chem. Soc. 119, 11571-11577.

  156. Baca, M., Scanlan, T.S., Stephenson, R.C. & Wells, J.A. (1997).  Phage display of a catalytic antibody to optimize affinity for transition-state analog binding.  Proc. Natl. Acad. Sci. 94, 10063-10068.

  157. Paech, K., Webb, P., Kuiper, G.G.J.M., Nilsson, S., Gustafsson, J.-Å., Kushner, P.J. & Scanlan, T.S. (1997).  Differential ligand activation of estrogen receptors ERa and ERb at AP1 sites.  Science 277, 1508-1510.

  158. Miller, S.C. & Scanlan, T.S. (1997).  Site-selective N-methylation of peptides on solid support.  J. Am. Chem. Soc. 119, 2301-2302.

  159. Wade, H. & Scanlan, T.S. (1997).  The structural and functional basis of antibody catalysis.  Annu. Rev. Biophys. Biomol. Struct. 26, 461-493.

  160. Wade, H. & Scanlan, T.S. (1996). P1-S1 interactions control the enantioselectivity and hydrolytic activity of the norleucine phenylesterase 17E8.  J. Am. Chem. Soc. 118, 6510-6511.

  161. Scanlan, T.S. (1995). Catalytic Antibodies. Ann. Rep. Med. Chem. 30, 255-264

  162. Scanlan, T.S. & Reid, R.C. (1995). Evolution in action. Chemistry & Biology 2, 71-75.

  163. Williard, R., Jammalamadaka, V., Zava, D., Hunt, C.A., Benz, C.C., Kushner, P.J. & Scanlan, T.S. (1995). Screening and characterization of estrogenic activity from a hydroxystilbene library. Chem. Biol. 2, 45-51.

  164. Guo, J., Huang, W., Zhou, G.W., Fletterick, R.J. & Scanlan, T.S. (1995). Mechanistically different catalytic antibodies obtained from immunization with the same transition state analog. Proc. Natl. Acad. Sci. 92, 1694-1698.

  165. Zhou, G.W., Guo, J., Huang, W., Fletterick, R.J. & Scanlan, T.S. (1994). Crystal structure of a catalytic antibody with a serine protease active site. Science 265, 1059-1064.

  166. Guo, J., Huang, W. & Scanlan, T.S. (1994). Kinetic and mechanistic characterization of an efficient hydrolytic antibody:  evidence for the formation of an acyl intermediate. J. Am. Chem. Soc. 116, 6062-6069.

  167. Santi, D.V., Ouyang, T.M., Tan, A.K., Gregory, D.H., Scanlan, T.S. & Carreras, C.W. (1993). Interaction of thymidylate synthase with pyridoxal-5'-phosphate as studied by UV/VIS difference spectroscopy and molecular modeling. Biochemistry 32, 11819-11824.

  168. Scanlan, T.S. & Schultz, P.G. (1992). Recent advances in catalytic antibodies. In Advances in Detailed Reaction Mechanisms volume 2:  Mechanisms of Biological Importance. (J. A. Coxon, ed.), pp. 1-22, JAI Press, London.

  169. Scanlan, T.S., Prudent, J.R. & Schultz, P.G. (1991). Antibody-catalyzed hydrolysis of phosphate monoesters. J. Am. Chem. Soc. 113, 9397-9398.

  170. Scanlan, T.S. & Schultz, P.G. (1991). Recent advances in catalytic antibodies. Phil. Trans. R. Soc. Lond. B 332, 157-164.

  171. Shokat, K.M., Ko, M.K., Scanlan, T.S., Kochersperger, L., Yonkovich, S., Thaisvirongs, S. & Schultz, P.G. (1990). Catalytic antibodies:  a new class of transition state analogs used to elicit hydrolytic antibodies. Angew. Chem. Int. Ed. Engl. 29, 1296-1303.

  172. Trost, B.M. & Scanlan, T.S. (1989). Stereoelectronic requirements of a Pd(0)-catalyzed cyclization.  A synthesis of allo-pumiliotoxin 339B. J. Am. Chem. Soc. 111, 4988-4990.

  173. Trost, B.M. & Scanlan, T.S. (1986). Synthesis of allyl sulfides via a palladium mediated allylation. Tetrahedron Lett. 27, 4141-4144.

bottom of page